Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

821 questions · 842 findings · 96 reviews

No studies found 275 · 32.7%GRADE not reported 88 · 10.5%Very low 197 · 23.4%Low 187 · 22.2%Moderate 86 · 10.2%High 9 · 1.1%

CBT vs alternative treatment

Additional physical symptoms · People aged 12 years and over with painful TMD lasting 3 months or longer

The review found no eligible studies for this question.

1 finding from 1 review

CBT vs alternative treatment

Adverse events · People aged 12 years and over with painful TMD lasting 3 months or longer
1 finding from 1 review
  • SoF: 3 studies reported minor adverse events in the control group; 1 study reported minor adverse events in psychological therapy group; 1 study reported that there were no adverse events. Results: NCT00066937 minor…
    5 studies
    Very low

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Failure to induce clinical remission at end of study · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in failure to induce clinical remission at week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Adverse events up to week 10 · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in adverse events up to week 10 compared with placebo and two infusions of infliximab (moderate certainty).

1 finding from 1 review

Three infusions of natalizumab (300 mg) and two infusions of infliximab (5 mg/kg) vs placebo and two infusions of infliximab

Withdrawals due to adverse outcomes · Participants with active Crohn's disease despite current treatment with infliximab

Three infusions of natalizumab (300 mg) and two infusions of… showed no clear difference in withdrawal due to adverse events up to week 10 compared with placebo and two infusions of infliximab (low certainty).

1 finding from 1 review